| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 10g |
|
| ln Vitro |
Acyclovir decreases cell survival in a dose- and time-dependent manner in Jurkat, U937, and K562 leukemia cells (3–100 μM; 24-72 hours) [1]. Acyclovir (Acyclovir, 10-100 μM; 24-72 hours; Jurkat cells) raises the sub-G1 hypodiploid peak and stops the cell cycle in the G2/M and S phases by blocking DNA synthesis[1]. Apoptosis is induced by aciclovir (10-100 μM; 24-72 hours; Jurkat cells) via activating caspase-3 and causing nuclear DNA fragmentation [1].
|
|---|---|
| ln Vivo |
Acyclovir (20 mg/kg; oral; three times daily; for 10 days; BALB/c mice) treatment prevents the growth of skin lesions and causes the production of antibodies and DTH responses to become dissociated [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Jurkat, U937 and K562 Leukemia cell Tested Concentrations: 3, 10, 30 and 100 µM Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: demonstrated a dose and time dependent decrease in cell viability. Apoptosis analysis [3] Cell Types: Jurkat cells Tested Concentrations: 10 and 100 µM Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: caspase-3 activity increases and cleaves internucleosomal DNA. Cell cycle analysis[1] Cell Types: Jurkat cells Tested Concentrations: 10 and 100 µM Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: Dose-dependent accumulation of cells in S phase after 24 and 48 hrs (hours). After 72 hrs (hours), there was a dose-dependent increase in the sub-G1 hypodiploid peak. |
| Animal Protocol |
Animal/Disease Models: Specific pathogen-free balb/c (Bagg ALBino) mouse (7 weeks old) infected with HSV-1 [1]
Doses: 20 mg/kg Route of Administration: po (po (oral gavage)) Three times daily; for 10 days Experimental Results: Inhibits the development of skin lesions and causes a dissociation between DTH response and antibody production. |
| References |
[1]. Benedetti S, et, al. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity. Life Sci. 2018 Dec 15;215:80-85.
[2]. Suzuki M, et, al. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61. [3]. Li Z, et, al. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus. Antivir Chem Chemother. 1999 Sep;10(5):251-7. [4]. Lönnqvist B, et, al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer. 1993 May;1(3):139-44. |
| Molecular Formula |
C8H11N5O3
|
|---|---|
| Molecular Weight |
225.21
|
| Exact Mass |
225.0862
|
| CAS # |
59277-89-3
|
| Related CAS # |
Acyclovir-d4;1185179-33-2;Acyclovir sodium;69657-51-8;Acyclovir alaninate;84499-64-9
|
| SMILES |
O=C1NC(N)=NC2=C1N=CN2COCCO
|
| InChi Key |
MKUXAQIIEYXACX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)
|
| Chemical Name |
6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-
|
| Synonyms |
Activir ACV Acyclovir AciclovirNSC-645011 NSC645011NSC 645011Acycloguanosine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~222.02 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 20 mg/mL (88.81 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Solubility in Formulation 4: 20 mg/mL (88.81 mM) in 0.5% CMC/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4403 mL | 22.2015 mL | 44.4030 mL | |
| 5 mM | 0.8881 mL | 4.4403 mL | 8.8806 mL | |
| 10 mM | 0.4440 mL | 2.2202 mL | 4.4403 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06228430 | Not yet recruiting | Drug: Acyclovir 800 mg Tablet Drug: Zovirax™ 800 mg Tablet |
Healthy Volunteer | International Bio service | February 12, 2024 | Phase 1 |
| NCT06134492 | Recruiting | Drug: Acyclovir | Pneumonia, Viral Ventilator Associated Pneumonia |
Jena University Hospital | February 20, 2024 | Phase 3 |
| NCT05589688 | Not yet recruiting | Drug: Acyclovir | Obesity | University Hospital, Toulouse | January 2024 | Phase 1 |
| NCT06217406 | Not yet recruiting | Drug: Intravenous acyclovir (ACYCLOVIR ) |
Invasive Mechanical Ventilation HSV Throat Reactivation |
Assistance Publique - Hôpitaux de Paris | March 1, 2024 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
